Comparasion the effect of four different dose of metaraminol for preventing post-spinal in cesarean section

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033888

Enrollment

Unknown

Registered

2020-06-15

Start date

2020-06-30

Completion date

Unknown

Last updated

2020-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Interventions

Group M1:0.5ug/kg·min metaraminol

Group M2:1.0 ug/kg·min metaraminol

Group M3:1.5 ug/kg·min metaraminol

Group M4:2.0 ug/kg·min metaraminol

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Pregnant women with full-term Singleton; 2. ASA level I-II; 3. Pregnant women aged 18-36 who underwent selective cesarean section.

Exclusion criteria

Exclusion criteria: 1. Obese subjects (BMI > 35 kg / m2); 2. Objects with height 175cm; 3. Patients with severe cardiovascular and cerebrovascular diseases; 4. Patients with hypertension and diabetes; 5. Patients with obstetric complications (placenta previa, placental abruption, etc.); 6. Pregnant women with known intrauterine fetal abnormalities; 7. Pregnant women with intrauterine growth restriction; 8. Pregnant women with contraindications of epidural puncture and subarachnoid puncture.

Design outcomes

Primary

Measure	Time frame
blood presure;	—

Secondary

Measure	Time frame
side effects;hemodynamics;	—

Countries

China

Contacts

Public ContactChai Xiaoqing

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

xiaoqingchai@ustc.edu.cn+86 551-62283912

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026